Bio-on spa

bio-on.it

Bio-On S.p.A., an Italian Intellectual Property Company (IPC), operates in the bioplastic sector conducting applied research and development of modern bio-fermentation technologies in the field of eco-sustainable and completely naturally biodegradable materials. In particular, Bio-On develops industrial applications through the creation of product characterizations, components and plastic items. Since February 2007, Bio-On S.p.A. has also been operating in the development of natural and sustainable chemicals for the future. Bio-On has developed an exclusive process for the production of a family of polymers called PHAs

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech

NEUMORA THERAPEUTICS ANNOUNCES $112 MILLION SERIES B FINANCING

Neumora | October 12, 2022

news image

Neumora Therapeutics, Inc. a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience, today announced the close of a $112 million Series B financing. The Series B syndicate includes both new and existing investors, such as Abu Dhabi Growth Fund Altitude Life Science Ventures, Amgen, ARCH Venture Partners, Exor Ventures, F-Prime Capital, Invus, Mubadala Capital, Newpath Partners, Polaris Partners and other und...

Read More

Medical

ACROBAT GENOMICS, NANOSTRING, AND ILLUMINA ACCELERATOR COLLABORATE WITH STANFORD MEDICINE TO DISCOVER NEW DRUG TARGETS

Businesswire | June 09, 2023

news image

Acrobat Genomics, NanoString Technologies, Inc. and the Illumina Accelerator announced today their collaboration with Stanford Medicine to discover new drug targets for gene editing-based therapeutics using GeoMx® Digital Spatial Profiling (DSP) technology. This collaboration aims to improve treatment options for patients suffering from interstitial lung diseases, such as idiopathic pulmonary fibrosis. NanoString’s GeoMx DSP is a powerful spatial biology platform that ...

Read More

AVM BIOTECHNOLOGY HIRES EXECUTIVE TEAM FOR ONCOLOGY & COVID-19 CLINICAL TRIALS

AVM Biotechnology | July 09, 2020

news image

Seattle's AVM Biotechnology, an up-and-coming biotech firm whose lead molecule, AVM0703, has received FDA permission to begin clinical trials treating no-option Non-Hodgkin's Lymphoma and is applying to begin trials treating moderate-severely ill COVID-19 patients, announced today the hiring of Janet R. Rea, MSPH, as Chief Operating Officer. As COO, Rea will lead operations and direct regulatory affairs as the company conducts clinical trials and brings AVM0703 to market."I am...

Read More

MedTech, Industrial Impact

ARCUTIS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION FOR ZORYVE® (ROFLUMILAST) CREAM 0.3% FOR EXPANDED INDICATION FOR THE TREATMENT OF PLAQUE PSORIASIS

Arcutis Biotherapeutics, Inc. | December 20, 2022

news image

Arcutis Biotherapeutics, Inc. an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced the submission of a supplemental new drug application to the U.S. Food and Drug Administration for the expanded indication of ZORYVE cream 0.3% for the treatment of plaque psoriasis in children ages 2 to 11. As with adults and adolescents, plaque psoriasis is the most common form of psoriasis in children 2 to 11 years of age, with very si...

Read More
news image

MedTech

NEUMORA THERAPEUTICS ANNOUNCES $112 MILLION SERIES B FINANCING

Neumora | October 12, 2022

Neumora Therapeutics, Inc. a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience, today announced the close of a $112 million Series B financing. The Series B syndicate includes both new and existing investors, such as Abu Dhabi Growth Fund Altitude Life Science Ventures, Amgen, ARCH Venture Partners, Exor Ventures, F-Prime Capital, Invus, Mubadala Capital, Newpath Partners, Polaris Partners and other und...

Read More
news image

Medical

ACROBAT GENOMICS, NANOSTRING, AND ILLUMINA ACCELERATOR COLLABORATE WITH STANFORD MEDICINE TO DISCOVER NEW DRUG TARGETS

Businesswire | June 09, 2023

Acrobat Genomics, NanoString Technologies, Inc. and the Illumina Accelerator announced today their collaboration with Stanford Medicine to discover new drug targets for gene editing-based therapeutics using GeoMx® Digital Spatial Profiling (DSP) technology. This collaboration aims to improve treatment options for patients suffering from interstitial lung diseases, such as idiopathic pulmonary fibrosis. NanoString’s GeoMx DSP is a powerful spatial biology platform that ...

Read More
news image

AVM BIOTECHNOLOGY HIRES EXECUTIVE TEAM FOR ONCOLOGY & COVID-19 CLINICAL TRIALS

AVM Biotechnology | July 09, 2020

Seattle's AVM Biotechnology, an up-and-coming biotech firm whose lead molecule, AVM0703, has received FDA permission to begin clinical trials treating no-option Non-Hodgkin's Lymphoma and is applying to begin trials treating moderate-severely ill COVID-19 patients, announced today the hiring of Janet R. Rea, MSPH, as Chief Operating Officer. As COO, Rea will lead operations and direct regulatory affairs as the company conducts clinical trials and brings AVM0703 to market."I am...

Read More
news image

MedTech, Industrial Impact

ARCUTIS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION FOR ZORYVE® (ROFLUMILAST) CREAM 0.3% FOR EXPANDED INDICATION FOR THE TREATMENT OF PLAQUE PSORIASIS

Arcutis Biotherapeutics, Inc. | December 20, 2022

Arcutis Biotherapeutics, Inc. an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced the submission of a supplemental new drug application to the U.S. Food and Drug Administration for the expanded indication of ZORYVE cream 0.3% for the treatment of plaque psoriasis in children ages 2 to 11. As with adults and adolescents, plaque psoriasis is the most common form of psoriasis in children 2 to 11 years of age, with very si...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us